Expanded Access to Epcoritamab
NCT05692050 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2023-02-03
Summary
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to epcoritamab prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Conditions
Interventions
- DRUG
-
Epcoritamab
Subcutaneous Injection
Sponsors & Collaborators
-
Genmab
collaborator INDUSTRY - lead INDUSTRY
Principal Investigators
-
ABBVIE INC. · AbbVie
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
NCT04628494 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
NCT06830759 ·Status: RECRUITING
-
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
NCT04542824 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
NCT06238648 ·Status: RECRUITING ·Phase: PHASE2
-
Epcoritamab in Previously Treated WM
NCT06510491 ·Status: RECRUITING ·Phase: PHASE2
-
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
NCT04623541 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Outpatient Epcoritamab as 2L in NTE R/R DLBCL
NCT06811272 ·Status: RECRUITING ·Phase: PHASE2
-
Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol
NCT04400591 ·Status: AVAILABLE
-
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel
NCT05776160 ·Status: AVAILABLE
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
NCT06510361 ·Status: RECRUITING ·Phase: PHASE2
-
Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL
NCT06287398 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma
NCT05451810 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade)
NCT00044902 ·Status: COMPLETED ·Phase: PHASE2
-
Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma
NCT07126236 ·Status: RECRUITING ·Phase: PHASE2
-
Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma
NCT00022685 ·Status: UNKNOWN ·Phase: PHASE3
-
Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab
NCT06931652 ·Status: RECRUITING ·Phase: PHASE2
-
Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab
NCT05206357 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study of LY3039478 in Participants With Advanced Cancer
NCT01695005 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma
NCT05201248 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
NCT05409066 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
NCT05605899 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
NCT06045247 ·Status: RECRUITING ·Phase: PHASE2
-
Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma
NCT01092182 ·Status: COMPLETED ·Phase: PHASE2
-
Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma
NCT01665768 ·Status: COMPLETED ·Phase: PHASE2
-
Biomarkers in Patients With Diffuse Large B-Cell Lymphoma Treated With Combination Chemotherapy With or Without Rituximab
NCT01131208 ·Status: COMPLETED